Experimental oral drug to treat Covid-19 at the first sign of illness could be available by the end of the year, CEO Albert Bourla told CNBC on Tuesday.
The company, which developed the first authorized Covid-19 vaccine in the U.S. with German drugmaker BioNTech, began in March an early stage clinical trial testing a new antiviral therapy for the disease. The drug is part of a class of medicines called protease inhibitors and works by inhibiting an enzyme that the virus needs to replicate in human cells.
Protease inhibitors are used to treat other viral pathogens such as HIV and hepatitis C.
If clinical trials go well and the Food and Drug Administration approves it, the drug could be distributed across the U.S. by the end of the year, Bourla told CNBC’s “Squawk Box.”
News Source: cnbc